Fulgent Genetics, Inc. (FLGT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 400M 800M 1.2B Q3 '21: 1B Q4 '21: 992.6M Q1 '22: 953.4M Q2 '22: 925.1M Q3 '22: 802.9M Q4 '22: 619M Q1 '23: 364.9M Q2 '23: 307.4M Q3 '23: 286.4M Q4 '23: 289.2M Q1 '24: 287.5M Q2 '24: 290.7M Q3 '24: 277.8M Q4 '24: 283.5M Q1 '25: 292.4M Q2 '25: 303.2M Q3 '25: 315.5M Q4 '25: 322.7M Q1 '26: 320.3M Q2 '26: 323.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 300M 600M 900M Q3 '21: 830.7M Q4 '21: 777.1M Q1 '22: 734.2M Q2 '22: 681.8M Q3 '22: 543.5M Q4 '22: 366.9M Q1 '23: 143.2M Q2 '23: 98.5M Q3 '23: 92.2M Q4 '23: 104.5M Q1 '24: 107.7M Q2 '24: 113.7M Q3 '24: 100.6M Q4 '24: 107.2M Q1 '25: 113.5M Q2 '25: 121.4M Q3 '25: 130.1M Q4 '25: 130.9M Q1 '26: 124M Q2 '26: 115.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-300M 0 300M 600M 900M Q3 '21: 751M Q4 '21: 676M Q1 '22: 611M Q2 '22: 524.9M Q3 '22: 365.9M Q4 '22: 178.5M Q1 '23: -48.2M Q2 '23: -80.8M Q3 '23: -81M Q4 '23: -195.5M Q1 '24: -192.5M Q2 '24: -191.6M Q3 '24: -208.9M Q4 '24: -73.9M Q1 '25: -71.9M Q2 '25: -72.7M Q3 '25: -71M Q4 '25: -91.1M Q1 '26: -105.9M Q2 '26: -122.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-200M 0 200M 400M 600M Q3 '21: 569.3M Q4 '21: 507.4M Q1 '22: 460.7M Q2 '22: 392.4M Q3 '22: 271.6M Q4 '22: 143.4M Q1 '23: -25.9M Q2 '23: -48.7M Q3 '23: -63.5M Q4 '23: -167.8M Q1 '24: -165.9M Q2 '24: -163.4M Q3 '24: -165M Q4 '24: -42.7M Q1 '25: -40.8M Q2 '25: -51M Q3 '25: -43M Q4 '25: -60.5M Q1 '26: -73.8M Q2 '26: -84.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 90M 180M 270M Q3 '21: 205.2M Q4 '21: 215.5M Q1 '22: 219.2M Q2 '22: 243.4M Q3 '22: 259.5M Q4 '22: 252.1M Q1 '23: 221.7M Q2 '23: 208.9M Q3 '23: 194.2M Q4 '23: 184.8M Q1 '24: 179.8M Q2 '24: 177M Q3 '24: 177.2M Q4 '24: 176.3M Q1 '25: 179M Q2 '25: 181.8M Q3 '25: 185.4M Q4 '25: 191.8M Q1 '26: 196.3M Q2 '26: 208.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-250M 0 250M 500M 750M Q3 '21: 595.7M Q4 '21: 538.6M Q1 '22: 493.8M Q2 '22: 428.8M Q3 '22: 297.4M Q4 '22: 253.5M Q1 '23: 57.2M Q2 '23: 55.8M Q3 '23: 45.3M Q4 '23: 27M Q1 '24: 42.2M Q2 '24: 36.7M Q3 '24: 11M Q4 '24: 21.1M Q1 '25: 9.4M Q2 '25: -25.1M Q3 '25: 1.5M Q4 '25: -101.6M Q1 '26: -90.1M Q2 '26: -83.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-200M 0 200M 400M 600M Q3 '21: 554.1M Q4 '21: 514.8M Q1 '22: 476.1M Q2 '22: 410.8M Q3 '22: 277.4M Q4 '22: 234.7M Q1 '23: 41.8M Q2 '23: 31.5M Q3 '23: 21.5M Q4 '23: 4.8M Q1 '24: 17.9M Q2 '24: 11.7M Q3 '24: -28.7M Q4 '24: -19.3M Q1 '25: -31.6M Q2 '25: -60M Q3 '25: -19.8M Q4 '25: -124.2M Q1 '26: -113.2M Q2 '26: -103.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 21.6M Q2 '20: 22.9M Q3 '20: 23.5M Q1 '21: 30.8M Q2 '21: 30.8M Q3 '21: 31.2M Q1 '22: 31.2M Q2 '22: 31.2M Q3 '22: 30.9M Q1 '23: 29.5M Q2 '23: 29.8M Q3 '23: 30M Q1 '24: 29.8M Q2 '24: 30.1M Q3 '24: 30.4M Q1 '25: 30.8M Q2 '25: 30.5M Q3 '25: 30.7M Q1 '26: 30.9M Q2 '26: 28M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q3 '17: 0.00 Q4 '17: -0.14 Q1 '18: -0.26 Q2 '18: -0.32 Q3 '18: -0.29 Q4 '18: -0.31 Q3 '17 Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.